What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma

Summary: Prof Philippe Moreau from the University Hospital of Nantes in France discusses anti-CD38 antibody-based treatment approaches for newly diagnosed and relapsed/refractory multiple myeloma, moderated by Dr Neil Love.